Proteomics, the large scale study of the body's proteins, is hitting a new bottleneck as mass spectrometers grow faster: not the instruments themselves, but the sample preparation, data analysis, and cross lab standards needed to make protein based tests routine in clinical care.
For three decades, the field that studies the body's proteins at scale has lived or died by its instruments. The mass spectrometer, the lab workhorse that identifies and counts proteins by weighing their fragments, kept getting faster, more sensitive, and more accurate. So at this year's 74th American Society for Mass Spectrometry (ASMS) conference in San Diego, the most striking thing was what was no longer being argued about. The hardware, attendees said, is finally good enough. The new bottleneck is everything that surrounds it.
"I think mass spec is no longer the limitation. We have the sensitivity, the throughput, and the accuracy at discovery and targeted" levels, Jennifer Van Eyk, a professor of cardiology and director of the Advanced Clinical Biosystems Research Institute at Cedars-Sinai Health Sciences University, told Genetic Engineering & Biotechnology News (GEN) at the conference. The remaining problem, she and other researchers said, is making sense of what the instruments produce, in ways that survive contact with real clinical laboratories and real patients.
Proteomics has been pitched for years as a route to earlier cancer detection, sharper cardiac risk assessment, and treatment choices tailored to a patient's molecular state. The instruments now exist to deliver on that promise. The reason it is not yet routine in hospitals is that the rest of the pipeline has not caught up.
That was the implicit theme running through the vendor floor in San Diego. Waters, Thermo Fisher Scientific, Sciex, Bruker, Biognosys, and Evosep all showed new or refined platforms, according to GEN's conference coverage, and the engineering priorities were familiar: faster acquisition, higher sensitivity, alternative fragmentation methods, spatial workflows that map proteins to specific tissue regions, and the software ecosystems that tie everything together. The instruments keep getting better. The story of ASMS 2026, as GEN's reporting framed it, is that the field has largely accepted that instrument speed is no longer the rate-limiting step.
The hard part, the conference's reframing suggests, lives in three places.
First, sample preparation. The chemistry that turns a blood draw or a biopsy into something a mass spectrometer can read is still slow, variable, and operator-dependent. Two labs running the same protocol on the same sample can return meaningfully different protein lists. Until that gap closes, scaling proteomics beyond research centers remains hard.
Second, data analysis. Modern instruments generate data faster than most clinical laboratories can store, let alone interpret. Turning raw spectra into a confidently identified and quantified protein list still depends on specialized software, curated reference libraries, and analysts who understand both the biology and the instrument. That talent and tooling bottleneck is why, in practice, a single clinical proteomics run can take days rather than the hours the hardware now allows.
Third, and most consequentially for the clinic, standardization and quality control. There is no equivalent, yet, of the calibration and reference standards that make a blood glucose test trustworthy across hospitals. Different labs use different sample handling, different instruments, different software, and different reporting units. Regulators and clinicians cannot compare results across sites, and that is the problem the field will have to solve if proteomics is going to be ordered, billed, and acted on the way a cholesterol panel is.
Van Eyk's point was not that the field is finished. It was that the conversation has changed. The instruments can now do the work. The work that remains, building a proteomics assay that any qualified lab can run, that any hospital can trust, and that any clinician can act on, is a different kind of problem. It is a workflow, software, and harmonization problem, not a physics problem.
That is also where the legitimate critique sits. The same conference that articulated the post-instrument reframing is a meeting built around vendor hardware announcements and poster sessions that have not been peer reviewed. The thesis that the bottleneck has moved is a senior researcher's read on where the field actually is, echoed by others, not a settled consensus. Whether the post-instrument frame survives contact with a regulatory pathway, a reimbursement decision, and a multi-site clinical trial is the question that will determine whether proteomics becomes a routine clinical tool within a decade or stays a powerful research technique for the foreseeable future.
The next round of large clinical proteomics studies will show whether harmonized, cross-site results are finally achievable, or whether the lab-to-lab variability that still dogs the field will persist. And the next wave of platform releases, at ASMS 2027 or in vendor announcements before then, will reveal whether the industry is starting to ship standardized sample-to-answer workflows rather than just faster instruments.